Cancer treatment company plans for public offeringJuly 25, 2019PetCure Oncology has engaged Boustead Securities for a Regulation D 506(c) offering.
SPONSORED CONTENTFind success with your parvovirus protocolDiscover our Canine Parvovirus Monoclonal Antibody: puppies treated with CPMA experienced a 93% real-world survival rate, and were able to head home from the clinic almost two days earlier.1,2 + Read More